Eurobio Scientific, leading French group in the fields of specialty in vitro medical diagnostics and life sciences, announces that it acquired Dendritics, a French company based in Lyon, specializing in antibody development and production. This acquisition was paid in cash, with no significant impact on the group’s cash position.
A company recognized in the field of monoclonal antibodies
With a proprietary technology, Dendritics developed a wide range of antibodies, mainly targeting immune system cells. These antibodies are unique tools, critical for researchers working in the healthcare industry, particularly for the discovery of targets with high diagnostic, prognostic and therapeutic potential. In 2017, the company achieved a turnover of approximately 350 KâĴ.
Assets for business development in North America and internationally
This acquisition enhances the Group’s proprietary products catalog and complements its custom manufacturing offering with high quality human and murine antibodies. It enables Eurobio Scientific to offer researchers and clinicians innovative tools and to reposition its offer as closely as possible to public and private life sciences players.
Building up on current Dendritics’ sales in the United States, Eurobio Scientific will also be able to develop its distribution network in this geographical area.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“This merger allows Eurobio Scientific to strengthen its production activities by offering custom antibody manufacturing services as well as an extensive portfolio of proprietary monoclonal antibodies. By using the innovative technology of Dendritics, we will also be able to develop new proprietary products, particularly in the field of diagnostics”, says Jean-Michel Carle, Chairman of Eurobio Scientific’s Management Board.
“For Dendritics, this merger is a major development opportunity drawing on the experience and commercial network of Eurobio Scientific. Our antibody offering and our innovative technology will thus be more accessible to researchers and clinicians, in France and abroad, thanks in particular to GenBio, the Group’s US subsidiary”, concludes Jean-Jacques Pin, President of Dendritics.
Date: July 23, 2018
Source: BioPortfolio